Bullish
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
Agomab Therapeutics has announced the design of its Phase 2b NOV-ERA study for ontunisertib, an investigational oral therapy for Fibrostenosing Crohn’...